AstraZeneca
Debate between Lindsay Hoyle and Chi Onwurah(1 day, 10 hours ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Urgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Chi Onwurah (Newcastle upon Tyne Central and West) (Lab)
The UK Government are committed to growing the economy through increased R&D and advanced manufacturing. AstraZeneca tell us that it is committed to investing in the UK, which is where it is headquartered and where one of its largest customers—the NHS—is based. It is like hearing that two people are madly in love with each other, yet the wedding is off. I look forward to the Minister of State for Science explaining the background to this to the Select Committee when he appears before us next week.
In the meantime, will the Minister confirm that the UK is committed to incentivising R&D investment? Will he set out the mix of R&D and manufacturing investment agreed to by AstraZeneca under the last Government, and to which it was committed when it dropped the deal? Finally, the deal, as well as growing the economy, would have made our pandemic supply chain more resilient by reducing our dependence on mRNA vaccines. Will he set out how he intends to address that?
Chris Bryant
It is good to hear from the Chair of the Select Committee. I want to make it absolutely clear that AstraZeneca is not leaving—people are not losing their jobs because of this decision. There are still 10,000 people employed by AstraZeneca in the UK and, for that matter, it is proceeding with its nasal-based flu vaccine for children, just in a different way. All of that is important.
My hon. Friend asked about the precise details of the R&D mix that was part of the investment. As I said, it was to have been £150 million of investment. AstraZeneca decided to cut that to £90 million, which is why the contribution that the previous Chancellor had suggested of £90 million into that pot simply did not add up for the UK taxpayer, which is why we came to that set of decisions. However, she is absolutely right that we are fundamentally committed to the life sciences sector for the saving of life, for making sure that we have an NHS that can really deliver for people, and because we want to have valuable jobs that we do better in this country than anywhere else in the world.
Oral Answers to Questions
Debate between Lindsay Hoyle and Chi Onwurah(3 weeks, 6 days ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Chi Onwurah (Newcastle upon Tyne Central and West) (Lab)
Last month, the Select Committee brought festive cheer by hearing how British science is advancing the eradication of diseases such as cervical cancer, HIV/AIDS and malaria, through innovative and exciting new treatments and diagnostics. We also heard about the challenges of driving innovation through the NHS. Newcastle company AMLo Biosciences said that adoption is much quicker in the US, and others criticised bureaucratic procurement processes and a culture of inertia. Successive Governments have struggled with this challenge, so what specific steps is the Secretary of State taking with the Health Secretary to ensure that British patients benefit from innovation?
Oral Answers to Questions
Debate between Lindsay Hoyle and Chi Onwurah(2 months, 2 weeks ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Mr Speaker
Order. Sorry—we have not reached that question. I call the Chair of the Science, Innovation and Technology Committee.
Chi Onwurah (Newcastle upon Tyne Central and West) (Lab)
My hon. Friend the Member for Folkestone and Hythe (Tony Vaughan) rightly raises the need for research into frontier AI safety, and I welcome the Government’s commitment to protecting the public from future AI risks. But AI affects all of our lives already. Today, my Committee launches an inquiry into algorithms, AI and their role in spreading online harm, as we saw in the terrible riots over the summer. As we build our evidence, how is the Minister building the evidence base on AI online harms and their social impact right now?
Oral Answers to Questions
Debate between Lindsay Hoyle and Chi Onwurah(3 months, 2 weeks ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Chi Onwurah (Newcastle upon Tyne Central and West) (Lab)
The whole House recognises—certainly, the Government’s industrial strategy does—that in order to drive growth we need innovation clusters across the country. The last Government committed to increasing R&D spend outside of the greater south-east by 40% by 2030 as part of the failed levelling-up strategy. Will the Secretary of State say whether he intends to maintain that target, and/or what steps he will take to ensure that funding is available to drive regional growth and innovation?